Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 – testing safety in a small group of people
Conditions:
Renal Cell Carcinoma
Urothelial Carcinoma
Castration-resistant Prostate Cancer
Sponsor: Deciphera Pharmaceuticals, LLC
trial.available_in:
БГ
Overview
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Who can participate
Key Inclusion Criteria:
* Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
* Able to take oral medication
* If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
* Adequate organ function and electrolytes
Key Exclusion Criteria:
* Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
* Impaired cardiac function
* Major surgery within 28 days of the first dose of study drug
БГ